Clinical Trials Logo

Filter by:
NCT ID: NCT00498836 Completed - Malignant Melanoma Clinical Trials

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.

NCT ID: NCT00498797 Completed - Prostate Cancer Clinical Trials

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.

NCT ID: NCT00496769 Completed - Atrial Fibrillation Clinical Trials

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

AVERROES
Start date: August 31, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.

NCT ID: NCT00496470 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease, COPD

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Start date: May 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the effect of combined treatment with Symbicort and Spiriva, in terms of improvement of lung function, symptoms and inflammatory markers, in patients with severe COPD.

NCT ID: NCT00494949 Completed - Hypotension Clinical Trials

Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients

Start date: April 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and possible effectiveness of Hemospan solution in patients undergoing elective orthopedic surgery who receive spinal anesthesia.

NCT ID: NCT00494793 Completed - Open Abdomen Clinical Trials

Vacuum Assisted Wound Closure (VAWC) and Mesh Mediated Fascial Traction

Start date: April 1, 2006
Phase: N/A
Study type: Interventional

The purpose of this multicenter trial is to prospectively evaluate a novel combination of vacuum assisted wound closure (VAWC) and mesh mediated fascial traction for closure of open abdomens.

NCT ID: NCT00494481 Completed - Clinical trials for Advanced Breast Cancer

E3 Breast Cancer Taxotere Combination

Start date: January 2006
Phase: Phase 2
Study type: Interventional

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

NCT ID: NCT00494442 Completed - Ovarian Neoplasm Clinical Trials

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

ICEBERG 2
Start date: June 11, 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.

NCT ID: NCT00494234 Completed - Breast Neoplasms Clinical Trials

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

ICEBERG 1
Start date: June 15, 2007
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists.

NCT ID: NCT00493077 Completed - Multiple Sclerosis Clinical Trials

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

SAFE
Start date: May 2004
Phase: Phase 4
Study type: Interventional

This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment